Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab

Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center and Mereo BioPharma Group plc MREO, has entered into a funding agreement.
The partnership will support a Phase 1b/2 clinical study of etigilimab combined with an anti-PD-1 antibody in clear cell ovarian cancer to be conducted at MD Anderson.
Cancer Focus Fund will finance the study in exchange for upfront consideration of $1.5 million of Mereo shares and additional payments based on the achievement of certain milestones.
Price Action: MREO shares are down 0.23% at $3.6 in the premarket trading on the last check Friday.